Ardelyx (NASDAQ:ARDX) Price Target Cut to $14.00 by Analysts at BTIG Research

Ardelyx (NASDAQ:ARDX) had its price objective lowered by BTIG Research from $17.00 to $14.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a report on Friday. Zacks Research lowered Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. LADENBURG THALM/SH SH initiated coverage on Ardelyx in a research report on Tuesday, June 16th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Weiss Ratings downgraded Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.30.

Ardelyx Stock Down 17.9%

ARDX opened at $4.00 on Friday. Ardelyx has a 52 week low of $3.90 and a 52 week high of $8.40. The business has a 50 day moving average price of $5.37 and a two-hundred day moving average price of $6.08. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37. The company has a market cap of $988.12 million, a PE ratio of -18.18 and a beta of 0.70.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 35.57%. The company had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. During the same period in the previous year, the firm posted ($0.08) EPS. The company’s revenue for the quarter was up 34.3% on a year-over-year basis. As a group, research analysts anticipate that Ardelyx will post -0.08 EPS for the current year.

Insider Activity

In other news, insider Eric Duane Foster sold 7,998 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the sale, the insider owned 417,972 shares of the company’s stock, valued at $2,620,684.44. The trade was a 1.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mike Kelliher sold 7,248 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total value of $45,444.96. Following the sale, the insider directly owned 357,418 shares in the company, valued at $2,241,010.86. This trade represents a 1.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 24,572 shares of company stock worth $154,066 over the last 90 days. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Ardelyx

A number of institutional investors have recently bought and sold shares of the company. Knott David M Jr acquired a new position in shares of Ardelyx during the 1st quarter worth $1,240,000. AIGH Capital Management LLC grew its stake in Ardelyx by 479.3% in the 4th quarter. AIGH Capital Management LLC now owns 1,150,000 shares of the biopharmaceutical company’s stock valued at $6,704,000 after acquiring an additional 951,500 shares during the last quarter. Vanguard Group Inc. increased its holdings in Ardelyx by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company’s stock valued at $110,650,000 after acquiring an additional 610,162 shares in the last quarter. Rubric Capital Management LP purchased a new position in Ardelyx during the 1st quarter valued at about $11,147,000. Finally, Tudor Investment Corp ET AL acquired a new position in Ardelyx during the third quarter worth about $688,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.